Talquetamab is a bispecific T-cell engager approved for relapsed or refractory multiple myeloma. This page compares Talquetamab to other agents in its class, including Teclistamab (Tecvayli), Elranatamab (Elrexfio), and Linvoseltamab (Lynozyfic). These agents exhibit distinct target specificities and administration schedules.
Talquetamab Alternatives: How It Compares to Other Bispecific Antibodies
Hipa.ai Research · Source: ClinicalTrials.gov / AACT · Last updated: AI-augmented data · 0/7 curated
Source: ClinicalTrials.gov via AACT · Hipa.ai, 2026-05-07Download chart as PNG
The competitive landscape features approved therapies like Teclistamab (Tecvayli) from 2022 and Elranatamab (Elrexfio) from 2023, with Talquetamab also approved in 2023. Pipeline candidates Etentamig, Cevostamab, and Alnuctamab are currently in Phase 3, approximately 1-2 years behind these approved treatments.
Quick comparison table
| Drug | Class | Approved indications | Dosing | Year approved | Lead pivotal endpoint | Annual cost (rough) |
|---|---|---|---|---|---|---|
| Talquetamab (Talvey) | Bispecific T-cell engager | Relapsed or refractory multiple myeloma | 0.4 mg/kg weekly or 0.8 mg/kg biweekly subcutaneously after step-up phase | 2023 | 73.6% @ 6 months | $540k |
| Teclistamab (Tecvayli) | BCMA-directed CD3 bispecific T-cell engager | relapsed or refractory multiple myeloma | Step-up doses of 0.06 mg/kg and 0.3 mg/kg, followed by 1.5 mg/kg subcutaneously once weekly until disease progression or unacceptable toxicity (may be reduced to biweekly or monthly in responding patients) | 2022 | 89% @ 34.5 months | $474k |
| Elranatamab (Elrexfio) | BCMA-directed CD3 bispecific antibody | Multiple myeloma | Step-up doses of 12 mg on Day 1 and 32 mg on Day 4, followed by 76 mg subcutaneously once weekly starting on Day 8 through Week 24. After 24 weeks, responders may transition to 76 mg every 2 weeks, and subsequently every 4 weeks if response is maintained. | 2023 | 57.7% @ 11.1 months median follow-up | $330k |
| Linvoseltamab (Lynozyfic) | BCMAxCD3 bispecific antibody | Relapsed or refractory multiple myeloma | Intravenous infusion: 5 mg on day 1, 25 mg on day 8, 200 mg on day 15; then 200 mg weekly (weeks 4-13), every 2 weeks (weeks 14-24), and every 4 weeks thereafter (if VGPR or better is achieved). | 2025 | 70% @ median 13 months | $454k |
| Etentamig | BCMA-directed bispecific T-cell engager | — | 60 mg intravenously every 4 weeks | Pipeline | — | — |
| Cevostamab | Bispecific T-cell engager | — | Intravenous infusion | Pipeline | — | — |
| Alnuctamab | BCMAxCD3 bispecific antibody | — | — | Pipeline | — | — |
Cost estimates are list-price approximations and do not reflect rebates, formulary tier, or out-of-pocket costs after benefits. The class-typical lead-pivotal endpoint here is Overall Response Rate (ORR); cells render each drug's actual pivotal endpoint, which may differ. The "Year approved" column shows the FDA approval year for multiple myeloma specifically — drugs approved for other indications first appear with their this-indication date, or as Pipeline if not yet approved for this indication. Cross-trial comparisons can mislead — head-to-head Phase-3 data (when present) is below.
Talquetamab vs Teclistamab (Tecvayli)
The pivotal head-to-head evidence comes from a head-to-head Phase-3 trial (NCT05552222) enrolling 1,590 participants, primary completion 2031-04.
Primary-endpoint values for NCT05552222 are not yet posted in the AACT results database.
Source: ClinicalTrials.gov via AACT — pulled directly from the trial's posted results. View the full trial record.
Talquetamab vs Elranatamab (Elrexfio)
No head-to-head Phase-3 trial directly compares Talquetamab with Elranatamab.
In separate pivotal trials, Talquetamab reported 73.6% ORR at 6 months (NCT04634552) versus 57.7% ORR at 11.1 months median follow-up for Elranatamab (NCT04649359).
Cross-trial caveat: the two drugs were tested in different patient populations at different time points. Cross-trial comparisons of response rates can mislead — the only rigorous comparison is a head-to-head randomized trial.
Talquetamab vs Linvoseltamab (Lynozyfic)
No head-to-head Phase-3 trial directly compares Talquetamab with Linvoseltamab.
In separate pivotal trials, Talquetamab reported 73.6% ORR at 6 months (NCT04634552) versus 70% ORR at median 13 months for Linvoseltamab (NCT03761108).
Cross-trial caveat: the two drugs were tested in different patient populations at different time points. Cross-trial comparisons of response rates can mislead — the only rigorous comparison is a head-to-head randomized trial.
Pipeline alternatives
Several investigational IL-17 / IL-17-related drugs are currently in active Phase 3 development. These include Etentamig from AbbVie, with its lead Phase 3 trial identified as NCT06158841. Also in Phase 3 is Cevostamab from Hoffmann-La Roche, with its lead trial NCT07555938. Alnuctamab is another investigational drug in Phase 3 development, though its sponsor is currently unknown. These agents are generally considered to be approximately 1-2 years behind Talquetamab in their development timelines. For instance, Alnuctamab operates via a different mechanism as an IL-17A nanobody.
Choosing between Talquetamab and its alternatives
When considering bispecific antibodies for multiple myeloma, Talquetamab, described as a bispecific T-cell engager, may be a consideration, particularly when a non-BCMA target is clinically relevant. The comparators, including Teclistamab, Elranatamab, and Linvoseltamab, are all specified as BCMA-directed CD3 bispecific antibodies. This mechanistic difference for Talquetamab could guide selection for patients who have progressed on BCMA-directed therapies or for whom a distinct target is preferred.
Conversely, clinicians may opt for a BCMA-directed bispecific antibody when that target is deemed appropriate for the patient. Teclistamab (Tecvayli) has demonstrated an overall response rate of 89% with a median follow-up of 34.5 months. It is dosed subcutaneously once weekly after step-up doses, with potential reduction to biweekly or monthly for responding patients. Elranatamab (Elrexfio) achieved an overall response rate of 57.7% with 11.1 months median follow-up, also administered subcutaneously once weekly through Week 24, with potential for biweekly or monthly dosing thereafter. Linvoseltamab (Lynozyfic), administered intravenously, showed an overall response rate of 70% with a median follow-up of 13 months, with weekly dosing initially, transitioning to less frequent administration for responders. The choice among these BCMA-directed agents may depend on specific efficacy expectations, administration route preferences, or the desired dosing frequency adjustments for maintenance.
Clinical decisions regarding specific therapies should always be made by the prescriber, taking into account the individual patient's condition, treatment history, and clinical context.
Sources and methodology
Trial data was pulled from the ClinicalTrials.gov registry via the AACT relational mirror maintained by the Clinical Trials Transformation Initiative. AACT data freshness: .
Head-to-head trials cited on this page:
- NCT05552222: Talquetamab vs Teclistamab · A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Dar…
Cross-trial comparison limitations:drugs without a direct head-to-head trial are compared using each drug's own pivotal trial. These trials enrolled different patient populations at different time points and used different statistical analysis sets. Cross-trial response-rate differences should not be interpreted as proof that one drug is more effective than another.
Related drug pages on Hipa.ai
Not medical advice. This page summarizes publicly-reported clinical trial data for informational purposes. Treatment decisions belong with a qualified prescribing clinician who knows your medical history. Drug approvals, dosing, and safety profiles change over time — always confirm with the current FDA prescribing information.
talquetamabtalquetamab alternativesalternativescomparisonmultiple myelomabispecific-multiple-myelomatalquetamab vs teclistamabtalquetamab vs elranatamabtalquetamab vs linvoseltamabtalquetamab vs etentamigtalquetamab vs cevostamab